ACADIA Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	375.65	391	226.45	-61.29	-215.98	-167.87
Depreciation & Amortization	11.8	11.76	15.88	5.55	-	3.34
Stock-Based Compensation	55.45	52.14	67.05	66.42	68.2	63.62
Other Adjustments	-3.76	-255.3	-155.82	-12.12	-4.25	0.08
Change in Receivables	-34.67	-43.54	-2.35	-39.27	2.26	-15.06
Changes in Inventories	-7.67	-18.2	-49.55	-28.81	2.42	-4.21
Changes in Accounts Payable	-5.85	-5.29	-1.35	4.8	5.87	-1.62
Changes in Accrued Expenses	4.41	-19.27	71.06	93.17	24.31	-8.46
Changes in Other Operating Activities	-23.24	-3.47	-13.66	-11.76	3.14	4.52
Operating Cash Flow	123.49	109.84	157.72	16.7	-114.04	-125.66
Operating Cash Flow Growth	-17.10%	-30.36%	844.31%	-	-	-
Capital Expenditures	-9.9	-4.69	-0.52	-0.05	-	-1.12
Sale of Property, Plant & Equipment	-	-	146.52	-	-	-
Purchases of Intangible Assets	-	-98.84	-	-40	-	-
Purchases of Investments	-551.56	-692.57	-505.1	-369.99	-363.17	-492.8
Proceeds from Sale of Investments	449.23	493.53	328.57	442.03	436.42	422.82
Investing Cash Flow	-112.23	-302.56	-30.54	32	73.24	-71.1
Issuance of Common Stock	52.28	49.88	6.85	25.13	8.2	18.16
Net Common Stock Issued (Repurchased)	52.28	49.88	6.85	25.13	8.2	18.16
Financing Cash Flow	52.28	49.88	6.85	25.13	8.2	18.16
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.06	0.03	-0.09	-0.02	0.01	0.01
Net Cash Flow	63.59	-142.82	133.93	73.81	-32.59	-178.59
Free Cash Flow	113.59	105.15	157.2	16.65	-114.04	-126.78
Free Cash Flow Growth	8.03%	-33.11%	844.01%	-	-	-
FCF Margin	10.37%	9.81%	16.41%	2.29%	-22.05%	-26.19%
Free Cash Flow Per Share	0.66	0.62	0.94	0.10	-0.71	-0.79
Levered Free Cash Flow	345.2	351.85	248.31	1.62	-180.25	-175.41
Unlevered Free Cash Flow	233.59	255.88	224.37	-25.21	-190.52	-178.34

SEC Filings: 10-K · 10-Q